RES logo
RES

RPC Inc

Energy

RPC Inc (RES) Stock News

The latest RES headlines and market coverage — 30 recent stories, updated throughout the day.

Showing 10 of 30 RES stories

Including: "Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis"

Sign up free to see all 30 + get insider-buy alerts.

Sign up free →